Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: Gary Vecchiarelli who wrote (9775)	7/20/1998 7:32:00 PM
From: Scott H. Davis	Respond to of 14328

Gary, best estimate I have is .02 unrounded last qtr, plus a 30% annual growth rate (per company exec in a conversation to me) = .0215. Since most people look at EPS as $ and Cents only, this is stil .02 rounded. Others later hearing company officialy quoting a 50%, would expect .0225, still .02 rounded. What's not clear is whether the 30 and 50% figures were for revenues or EPS. So if EPS is reported as .02, it will be the third straight .02. Don't think the market is going to go bonkers over that. You did not mention you timeframe for the $3.0 question, but since you refer to "once earnings come out" I assume you mean after this qtr. Unless they pull off a miracle and report .04 based on re-ocurring earnings, ain't a 10% chance it will go to $3 after this report, unless they pull off an FDA HIV approval out of the hat. IMSCO Scott Only positive thing I can say on a short/intermediate term basis is that support has held pretty well around 1 7/8. So if a load of additional convertibles don't hit (or cease) the downside is probably limited. Scott